Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital.

Jha AK, Sunder A

The Journal of the Association of Physicians of India1 Jun 2026

PMID42543936DOI10.59556/japi.74.1508PepBankPUB-42543936

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, mean HbA1c fell from 9.21% to 7.35% after six months of semaglutide.
In plain wordsIn adults with type 2 diabetes, average HbA1c fell after six months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c
Study
n = 60
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Mean HbA1c
9.21%
baseline
Mean HbA1c
7.35%
six months
Source sentences
Summary
Mean HbA1c decreased from 9.21% at baseline to 7.35% after six months (p <0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted at a tertiary care hospital in Jharkhand, India, between February 2023 and August 2024.
Summary · context
A total of 60 patients with T2DM (44 males and 16 females), including treatment-naïve individuals and those with inadequate glycemic control (HbA1c >7%) despite ongoing therapy, were enrolled.
Summary · context
Clinical and biochemical parameters were evaluated at baseline and after six months of semaglutide therapy.
Report a problemFND-4254393601
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, mean body weight fell by 2.6 kg after six months of semaglutide.
In plain wordsIn adults with type 2 diabetes, average body weight fell after six months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight
Study
n = 60
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Mean body weight change
−2.6 kg
six months
Source sentences
Summary
Mean body weight decreased by 2.6 kg (p <0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted at a tertiary care hospital in Jharkhand, India, between February 2023 and August 2024.
Summary · context
A total of 60 patients with T2DM (44 males and 16 females), including treatment-naïve individuals and those with inadequate glycemic control (HbA1c >7%) despite ongoing therapy, were enrolled.
Summary · context
Clinical and biochemical parameters were evaluated at baseline and after six months of semaglutide therapy.
Report a problemFND-4254393602
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, LDL cholesterol fell from 92.03 to 78.93 mg/dL after six months of semaglutide.
In plain wordsIn adults with type 2 diabetes, LDL cholesterol fell after six months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseLDL cholesterol
Study
n = 60
Comparator
Baseline
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
LDL cholesterol
92.03 mg/dL
baseline
LDL cholesterol
78.93 mg/dL
six months
Source sentences
Summary
LDL cholesterol levels declined significantly from 92.03 mg/dL to 78.93 mg/dL (p <0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted at a tertiary care hospital in Jharkhand, India, between February 2023 and August 2024.
Summary · context
A total of 60 patients with T2DM (44 males and 16 females), including treatment-naïve individuals and those with inadequate glycemic control (HbA1c >7%) despite ongoing therapy, were enrolled.
Summary · context
Clinical and biochemical parameters were evaluated at baseline and after six months of semaglutide therapy.
Report a problemFND-4254393603
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, serum creatinine showed numerical improvement that was not statistically significant.
In plain wordsIn adults with type 2 diabetes, a small change in kidney blood test results after semaglutide was not statistically significant.
Peptide
Semaglutide
Outcome
No significant changeSerum creatinine
Study
n = 60
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Renal parameters, including serum creatinine and urine albumin-to-creatinine ratio, showed numerical improvement; however, these changes did not reach statistical significance (p >0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted at a tertiary care hospital in Jharkhand, India, between February 2023 and August 2024.
Summary · context
A total of 60 patients with T2DM (44 males and 16 females), including treatment-naïve individuals and those with inadequate glycemic control (HbA1c >7%) despite ongoing therapy, were enrolled.
Summary · context
Clinical and biochemical parameters were evaluated at baseline and after six months of semaglutide therapy.
Report a problemFND-4254393604
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, urine albumin-to-creatinine ratio showed numerical improvement that was not statistically significant.
In plain wordsIn adults with type 2 diabetes, a small change in a kidney urine test after semaglutide was not statistically significant.
Peptide
Semaglutide
Outcome
No significant changeUrine albumin-to-creatinine ratio
Study
n = 60
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Renal parameters, including serum creatinine and urine albumin-to-creatinine ratio, showed numerical improvement; however, these changes did not reach statistical significance (p >0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted at a tertiary care hospital in Jharkhand, India, between February 2023 and August 2024.
Summary · context
A total of 60 patients with T2DM (44 males and 16 females), including treatment-naïve individuals and those with inadequate glycemic control (HbA1c >7%) despite ongoing therapy, were enrolled.
Summary · context
Clinical and biochemical parameters were evaluated at baseline and after six months of semaglutide therapy.
Report a problemFND-4254393605
06HumanObservational studySafety outcome
In adults with type 2 diabetes in routine care, thyroid function remained stable during semaglutide therapy.
In plain wordsIn adults with type 2 diabetes, thyroid function stayed stable during semaglutide treatment.
Peptide
Semaglutide
Outcome
No significant changeThyroid function
Study
n = 60
Comparator
Baseline
Outcome group
Adverse events · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Thyroid function remained stable throughout the study period.
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted at a tertiary care hospital in Jharkhand, India, between February 2023 and August 2024.
Summary · context
A total of 60 patients with T2DM (44 males and 16 females), including treatment-naïve individuals and those with inadequate glycemic control (HbA1c >7%) despite ongoing therapy, were enrolled.
Summary · context
Clinical and biochemical parameters were evaluated at baseline and after six months of semaglutide therapy.
Report a problemFND-4254393606
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, improvement in diabetic retinopathy was not statistically significant.
In plain wordsIn adults with type 2 diabetes, eye changes after semaglutide were not statistically significant.
Peptide
Semaglutide
Outcome
No significant changeDiabetic retinopathy
Study
n = 60
Comparator
Baseline
Outcome group
Diabetes complications · Eye
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Improvements in diabetic retinopathy and neuropathy were also observed, although these findings were not statistically significant.
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted at a tertiary care hospital in Jharkhand, India, between February 2023 and August 2024.
Summary · context
A total of 60 patients with T2DM (44 males and 16 females), including treatment-naïve individuals and those with inadequate glycemic control (HbA1c >7%) despite ongoing therapy, were enrolled.
Summary · context
Clinical and biochemical parameters were evaluated at baseline and after six months of semaglutide therapy.
Report a problemFND-4254393607
08HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, improvement in diabetic neuropathy was not statistically significant.
In plain wordsIn adults with type 2 diabetes, nerve symptom changes after semaglutide were not statistically significant.
Peptide
Semaglutide
Outcome
No significant changeDiabetic neuropathy
Study
n = 60
Comparator
Baseline
Outcome group
Diabetes complications · Nervous system and cognition
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Improvements in diabetic retinopathy and neuropathy were also observed, although these findings were not statistically significant.
3 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study was conducted at a tertiary care hospital in Jharkhand, India, between February 2023 and August 2024.
Summary · context
A total of 60 patients with T2DM (44 males and 16 females), including treatment-naïve individuals and those with inadequate glycemic control (HbA1c >7%) despite ongoing therapy, were enrolled.
Summary · context
Clinical and biochemical parameters were evaluated at baseline and after six months of semaglutide therapy.
Report a problemFND-4254393608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.